Oncology · NSCLCTrial Updateclinicalmid-term

Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/18/2026, 12:32:48 PM

Assessment confidence: 75% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of adagrasib combined with pembrolizumab and chemotherapy represents a significant advancement in the treatment of KRAS G12C mutated NSCLC. Positive results could enhance Mirati's competitive positioning and market share in the oncology sector. Regulatory context from FDA (FDA AP — PADCEV (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (5 high-relevance).

Strategic Assessment

Success in this trial could enhance Mirati's portfolio and market position in the oncology space, particularly for NSCLC treatments. The strongest clinical anchor is A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (ClinicalTrials.gov), sub-indication match (lung cancer). In lung cancer, 1 regulatory and 3 competitive items passed relevance filtering for Mirati Therapeutics.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sub-indication match (lung cancer); mechanism alignment (kras). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial positions Mirati Therapeutics to compete in the NSCLC market, particularly against other therapies targeting KRAS mutations.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PADCEV (SUPPL) (FDA). Regulatory pathway relevance (bla). If the trial demonstrates efficacy and safety, it could facilitate expedited regulatory approval, impacting the competitive landscape for NSCLC treatments.

Key Risks

Elevated medium regulatory exposure for Mirati Therapeutics could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

Success in this trial could lead to increased adoption of Mirati's therapies, potentially boosting revenue and market share in a lucrative oncology market.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
To compare the efficacy and safety of a sequential combination of chemoradiotherapy (CRT) with immune checkpoint inhibitors (ICIs) administered as induction plus consolidation versus consolidation-only in patients with unresectable stage III non-small cell lung cancer (NSCLC).
This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety data.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PADCEV (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (bla)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Other | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
ClinicalTrials.govmedium relevance
Sub-indication match (lung cancer)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Stepping Stones and Creating Futures Plus Pilot
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
KEYTRUDA Shows Significant PFS Improvement in dMMR Endometrial Cancer in Phase 3 Trial
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Sub-indication match (lung cancer); Entity match (pembrolizumab)
FDA document
View source
Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Phytotherapeutics self-microemulsifying systems in pellet dosage form for enhanced intestinal drug delivery: formulation, stability, and in-vivo performance.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mirati Therapeutics
Adagrasib
Pembrolizumab

Commercial impact

high

Success in this trial could lead to increased adoption of Mirati's therapies, potentially boosting revenue and market share in a lucrative oncology market.

Regulatory impact

medium

If the trial demonstrates efficacy and safety, it could facilitate expedited regulatory approval, impacting the competitive landscape for NSCLC treatments.

What to watch

Monitor trial results and any announcements regarding efficacy and safety data.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.